BioIndustry Ethics

• Chapter 1: INTRODUCTIONChapter 2: MERCK: STAYING THE COURSEChapter 3: GENZYME: PUTTING PATIENTS FIRSTChapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUESChapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUESChapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPSChapter 7: PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTSChapter 8: TGN BIOTECH: A START-UP WITH ETHICAL ROOTSChapter 9: INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIPChapter 10: SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCEChapter 11: AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICEChapter 12: PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARDChapter 13: MONSANTO COMPANY: BIO-AGRICULTURE PIONEERChapter 14: NOVO NORDISK: THE TRIPLE BOTTOM LINEChapter 15: CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUESINDEX

"Biotechnology and pharmaceutical companies are often driven by profit goals, but the case studies in Bioindustry Ethics show that this is increasingly not at the expense of ethical integrity. ...lend[s] important insights to other executives and professionals who might be developing their own practices and policies."- GENOMICS & PROTEOMICS (August 2005)